PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Infectious Diseases

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Pathology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions

Egyptian Board — Dermatology & Venereology (Part 1 & 2)

Practice Questions

Sample Egyptian Board Infectious Diseases Practice Questions

Try these sample questions to review concepts for the Egyptian Board Infectious Diseases exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1Which molecular target distinguishes the bactericidal mechanism of glycopeptides such as vancomycin from that of beta-lactam antibiotics during bacterial cell wall synthesis?
A.Terminal D-alanyl-D-alanine pentapeptide precursor side chains
B.Penicillin-binding protein transpeptidase active catalytic sites
C.Undecaprenyl pyrophosphate lipid carrier dephosphorylation cycles
D.N-acetylglucosamine-N-acetylmuramic acid disaccharide backbone polymerases
Explanation: Vancomycin exerts its bactericidal effect by binding with high affinity to the terminal D-alanyl-D-alanine moieties of cell wall peptidoglycan precursors. This steric hindrance prevents both transglycosylation and transpeptidation reactions. In contrast, beta-lactams bind directly to the catalytic active site of penicillin-binding proteins (transpeptidases) rather than binding the peptide substrate.
2A clinical isolate of Klebsiella pneumoniae demonstrates high-level resistance to amikacin, gentamicin, and tobramycin. Genetic sequencing confirms the presence of an armA gene. What is the precise biochemical mechanism of this resistance?
A.Active proton-dependent efflux through tripartite MexAB-OprM membrane pumps
B.16S ribosomal RNA methylation preventing drug binding to the 30S decoding A-site
C.Enzymatic O-adenylylation of the 2-deoxystreptamine aminoglycoside scaffold
D.Mutational alteration of the 50S L4/L22 ribosomal proteins disrupting translocation
Explanation: The armA gene encodes a 16S rRNA methyltransferase that methylates the G1405 nucleotide within the 30S ribosomal decoding region (A-site). This specific modification confers pan-aminoglycoside resistance across 4,6-disubstituted 2-deoxystreptamines, including amikacin, gentamicin, and tobramycin. Aminoglycoside-modifying enzymes typically confer narrower subclass-specific phenotypes.
3An isolate of Escherichia coli recovered from a bacteremic patient is resistant to ceftriaxone, ceftazidime, and aztreonam, but tests susceptible to piperacillin-tazobactam, cefepime, and ertapenem. Addition of clavulanic acid produces a >=5 mm increase in the zone diameter of ceftriaxone. Which resistance enzyme is most consistent with this phenotypic profile?
A.Chromosomal inducible class C beta-lactamase (AmpC)
B.Carbapenem-hydrolyzing class D oxacillinase (OXA-48)
C.Plasmid-mediated class A extended-spectrum beta-lactamase (CTX-M)
D.Acquired Ambler class B metallo-beta-lactamase (NDM-1)
Explanation: Extended-spectrum beta-lactamases (ESBLs, predominantly CTX-M variants) are Ambler class A serine enzymes that hydrolyze penicillins, oxyimino-cephalosporins (ceftriaxone, ceftazidime), and aztreonam. They are characteristically inhibited by beta-lactamase inhibitors like clavulanate and tazobactam, demonstrating synergistic zone expansion, and spare carbapenems. AmpC enzymes and metallo-beta-lactamases are not inhibited by clavulanic acid.
4A patient with Enterobacter cloacae complex urosepsis is initially treated with ceftriaxone based on an in vitro susceptible minimum inhibitory concentration (MIC 0.5 mcg/mL). On day 5 of therapy, repeat blood cultures remain persistently positive, and the organism is now resistant to ceftriaxone and piperacillin-tazobactam, but remains susceptible to cefepime and meropenem. What molecular event explains this clinical failure?
A.Horizontal acquisition of a transmissible IncP plasmid harboring blaKPC-2
B.Downregulation of outer membrane porin OmpF combined with basally expressed SHV-1
C.Loss of penicillin-binding protein 3 affinity due to an insertion in the ftsI gene
D.Spontaneous mutation in ampR or ampD leading to constitutional AmpC derepression
Explanation: Enterobacter cloacae complex harbors an inducible chromosomal ampC gene regulated by AmpR, AmpD, and AmpG. Exposure to beta-lactams or spontaneous mutations in the ampD repressor gene leads to stable, high-level constitutional derepression of AmpC beta-lactamase. Derepressed AmpC efficiently hydrolyzes 3rd-generation cephalosporins and beta-lactamase inhibitor combinations, but cefepime resists hydrolysis due to its zwitterionic structure and low enzyme affinity.
5According to the Ambler classification system for beta-lactamases, which enzyme class utilizes active-site divalent zinc ions rather than a catalytic serine residue to hydrolyze beta-lactam rings?
A.Class B metallo-beta-lactamases (e.g., NDM, VIM, IMP)
B.Class A carbapenemases (e.g., KPC, GES, SME)
C.Class C cephalosporinases (e.g., AmpC, CMY, ACT)
D.Class D oxacillin-hydrolyzing carbapenemases (e.g., OXA-48)
Explanation: Ambler class B enzymes are metallo-beta-lactamases (MBLs) that utilize divalent zinc cations (Zn2+) in their active site to coordinate and activate a water molecule that cleaves the beta-lactam ring. In contrast, classes A, C, and D are serine beta-lactamases that form a transient covalent acyl-enzyme intermediate through an active-site serine residue. MBLs are inhibited by metal chelators such as EDTA but not by serine beta-lactamase inhibitors.
6A blood culture from a liver transplant recipient flags positive for Klebsiella pneumoniae harboring both blaNDM-1 and blaCTX-M-15. Which antimicrobial regimen provides targeted microbiological activity against this dual-carbapenemase/ESBL-producing pathogen?
A.Meropenem-vaborbactam monotherapy
B.Aztreonam combined with ceftazidime-avibactam
C.Imipenem-cilastatin-relebactam monotherapy
D.High-dose extended-infusion cefepime monotherapy
Explanation: Metallo-beta-lactamases like NDM-1 hydrolyze all beta-lactams except aztreonam, but NDM-producing Enterobacterales almost universally co-produce serine beta-lactamases (such as CTX-M ESBLs or AmpC) that destroy aztreonam. Avibactam inhibits these co-produced serine enzymes, protecting aztreonam from degradation, while aztreonam is naturally stable against the NDM carbapenemase. Meropenem-vaborbactam and imipenem-relebactam are ineffective against metallo-beta-lactamases.
7What is the primary genetic and biochemical basis of methicillin resistance in Staphylococcus aureus (MRSA)?
A.Hyperproduction of BlaZ beta-lactamase hydrolyzing all penicillin derivatives
B.Methylation of the 23S rRNA subunit preventing beta-lactam binding
C.Acquisition of mecA encoding penicillin-binding protein 2a (PBP2a)
D.Active drug extrusion mediated by the plasmid-borne norA efflux pump
Explanation: Methicillin resistance in S. aureus is mediated by the acquisition of the staphylococcal cassette chromosome mec (SCCmec), which carries the mecA or mecC gene. These genes encode an altered penicillin-binding protein, PBP2a (or PBP2c), which exhibits markedly low binding affinity for virtually all standard beta-lactam antibiotics, allowing cell wall synthesis to proceed despite therapeutic beta-lactam concentrations. Ceftaroline is the only FDA-approved beta-lactam active against PBP2a.
8An isolate of Enterococcus faecium recovered from a bone marrow aspirate exhibits a vancomycin MIC of >256 mcg/mL and a teicoplanin MIC of 64 mcg/mL. PCR testing confirms the VanA operon. What specific biochemical modification to peptidoglycan precursors accounts for this high-level glycopeptide cross-resistance?
A.Replacement of terminal D-Ala-D-Ala with D-alanyl-D-serine causing a 10-fold drop in binding
B.Enzymatic phosphorylation of the D-alanyl side chain by VanY carboxypeptidase
C.Mutational truncation of the stem pentapeptide to a tripeptide lacking D-alanine
D.Substitution of terminal D-alanyl-D-alanine with D-alanyl-D-lactate reducing affinity by 1,000-fold
Explanation: The VanA phenotype confers high-level inducible resistance to both vancomycin and teicoplanin. The VanA ligase synthesizes depsipeptide cell wall precursors terminating in D-alanyl-D-lactate (D-Ala-D-Lac) instead of D-alanyl-D-alanine. This ester linkage eliminates a critical hydrogen bond, reducing glycopeptide binding affinity by approximately 1,000-fold. In contrast, the VanC phenotype produces D-Ala-D-Ser precursors, conferring low-level intrinsic vancomycin resistance without teicoplanin resistance.
9Which pharmacokinetic/pharmacodynamic (PK/PD) parameter best predicts the clinical bactericidal efficacy of once-daily high-dose aminoglycoside therapy, and which parameter correlates most closely with nephrotoxicity?
A.Peak concentration-to-MIC ratio (Cmax/MIC) for efficacy; trough concentration (Cmin) for nephrotoxicity
B.Time above MIC (%T > MIC) for efficacy; peak concentration (Cmax) for nephrotoxicity
C.Area under the curve-to-MIC ratio (AUC/MIC) for efficacy; total clearance for nephrotoxicity
D.Post-antibiotic effect duration for efficacy; free unbound drug fraction for nephrotoxicity
Explanation: Aminoglycosides exhibit concentration-dependent bactericidal killing; their clinical and microbiological efficacy is maximized when the peak concentration exceeds the organism's MIC by at least 8- to 10-fold (Cmax/MIC >= 8-10). Nephrotoxicity results from accumulation of drug in renal proximal tubular cells, which is driven by sustained trough levels (Cmin) rather than transient high peaks. Thus, once-daily extended-interval dosing achieves optimal Cmax while allowing prolonged drug clearance to undetectable troughs.
10A clinical isolate of Salmonella enterica serovar Typhi shows resistance to ciprofloxacin with an MIC of 4 mcg/mL. Which chromosomal mutations in the quinolone resistance-determining regions (QRDR) are most commonly responsible for high-level fluoroquinolone resistance in Enterobacterales?
A.Point mutations in the rpoB gene affecting RNA polymerase elongation
B.Point mutations in gyrA (DNA gyrase) and parC (topoisomerase IV)
C.Frameshift deletions in the ftsI gene disrupting transpeptidation
D.Tandem duplications in the folP gene increasing dihydropteroate synthase activity
Explanation: Fluoroquinolones inhibit bacterial DNA replication by trapping complexes of DNA gyrase (encoded by gyrA and gyrB) and topoisomerase IV (encoded by parC and parE). High-level fluoroquinolone resistance in Gram-negative bacilli results stepwise from point mutations within the quinolone resistance-determining regions (QRDR), typically involving Ser83 or Asp87 in gyrA and Ser80 in parC, which decrease drug binding affinity.

About the Egyptian Board Infectious Diseases Exam

The Egyptian Board in Infectious Diseases is the premier medical postgraduate qualification administered by the Egyptian Health Council (المجلس الصحي المصري) under Law No. 12 of 2022. It validates clinical mastery over acute and chronic infections, tropical medicine, healthcare epidemiology, emerging infectious pathogens, and rational antimicrobial utilization. The examination pathway comprises three progressive phases: Part 1 written basic sciences, Part 2 written clinical infectious diseases, and Part 3 comprehensive clinical OSCE, practical laboratory evaluation, and oral viva voce.

Exam sponsor: Egyptian Health Council (EHC) — Egyptian Board (المجلس الصحي المصري — البورد المصري). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board Infectious Diseases examination comprises three formal stages: Part 1 consists of written multiple-choice examinations covering medical microbiology, immunology, microbial genetics, and antimicrobial pharmacology. Part 2 features advanced multiple-choice questions assessing bedside diagnostic strategies, antibiogram interpretation, multidrug-resistant pathogen regimens, and endemic fever evaluations. Part 3 is a comprehensive clinical examination consisting of objective structured clinical examination (OSCE) stations, bedside clinical encounters, Gram stain/culture plate interpretations, and oral viva voce with senior academic examiners. Note that Part Three is entirely clinical, and the official board does not publish a standardized MCQ question count. This 100-question practice set is an English-language study aid dedicated to reinforcing key cognitive knowledge across Parts 1 and 2.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Prescribed by Egyptian Health Council regulatory bylaws

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

25%

General Microbiology, Antimicrobial Pharmacology & Stewardship

Bacterial, viral, fungal, and parasitic biology; mechanisms of antimicrobial action and resistance (ESBL, CRE, MRSA, VRE, MDR Pseudomonas/Acinetobacter); pharmacokinetic/pharmacodynamic (PK/PD) principles (time-dependent vs concentration-dependent bactericidal activity); antimicrobial stewardship interventions and therapeutic drug monitoring.

20%

Healthcare-Associated Infections & Infection Control

Hospital-acquired and ventilator-associated pneumonia (HAP/VAP); catheter-associated urinary tract infections (CAUTI); central line-associated bloodstream infections (CLABSI); surgical site infections; Clostridioides difficile infection; isolation precautions, outbreak investigations, and surveillance epidemiology.

20%

Community-Acquired Infections, Sepsis & Systemic Syndromes

Community-acquired pneumonia (CURB-65); infective endocarditis (modified Duke criteria, empirical and targeted regimens, surgical indications); central nervous system infections (meningitis, encephalitis, brain abscess); complicated skin/soft tissue and bone/joint infections (osteomyelitis, prosthetic joint infections); Sepsis-3 resuscitation bundles.

20%

HIV/AIDS, Opportunistic Infections & Immunocompromised Hosts

HIV diagnosis, staging, and antiretroviral therapy (ART) regimens; prevention and management of opportunistic infections (PCP, toxoplasmosis, cryptococcal meningitis, MAC, CMV); infections in neutropenic patients; solid organ transplant and hematopoietic cell transplant recipient infections.

15%

Tropical Infections, Mycobacterial Diseases & Travel Medicine

Tuberculosis (pulmonary, extrapulmonary, drug-resistant MDR/XDR-TB, latent TB screening and treatment); nontuberculous mycobacteria; typhoid fever and brucellosis; malaria diagnosis, speciation, and treatment; schistosomiasis, leishmaniasis, and viral hemorrhagic fevers; pre-travel immunizations and chemoprophylaxis.

Preparing for the Egyptian Board Infectious Diseases Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board Infectious Diseases examination comprises three formal stages: Part 1 consists of written multiple-choice examinations covering medical microbiology, immunology, microbial genetics, and antimicrobial pharmacology. Part 2 features advanced multiple-choice questions assessing bedside diagnostic strategies, antibiogram interpretation, multidrug-resistant pathogen regimens, and endemic fever evaluations. Part 3 is a comprehensive clinical examination consisting of objective structured clinical examination (OSCE) stations, bedside clinical encounters, Gram stain/culture plate interpretations, and oral viva voce with senior academic examiners. Note that Part Three is entirely clinical, and the official board does not publish a standardized MCQ question count. This 100-question practice set is an English-language study aid dedicated to reinforcing key cognitive knowledge across Parts 1 and 2.
  • Time limit: Varies by examination part
  • Exam / certification fees: Prescribed by Egyptian Health Council regulatory bylaws Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Infectious Diseases: Suggested Study Strategy

1Master PK/PD parameters (fAUC/MIC for vancomycin/fluoroquinolones, fT>MIC for beta-lactams, Cmax/MIC for aminoglycosides) to guide dosing.
2Consolidate treatment guidelines for MDR Gram-negative pathogens (carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii).
3Understand diagnostic criteria and empirical/targeted therapy for infective endocarditis, fever of unknown origin (FUO), and febrile neutropenia.
4Review regional endemic infections in Egypt, including brucellosis, typhoid, schistosomiasis, and zoonotic viral infections.

Frequently Asked Questions

What is the official question count for the Egyptian Board Infectious Diseases exam?

The Egyptian Health Council does not publish a fixed, standardized question count for its written examinations. Parts 1 and 2 written papers typically range between 100 and 200 MCQs. This platform provides 100 curated practice MCQs covering core high-yield curriculum objectives.

Does this practice test cover practical laboratory microbiology (Part 3)?

Part 3 is a practical and clinical examination involving microbiology bench stations, patient scenarios, and oral viva. This practice test is dedicated to mastering the theoretical and clinical knowledge tested in Parts 1 and 2.

What standard guidelines and textbooks are recommended?

Key recommended sources include Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, IDSA Guidelines, and WHO Infection Prevention and Control manuals.